Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion

In combination with the pharma giant’s checkpoint inhibitor Opdivo, Exelixis’s once-daily pill Cabometyx improved progression-free survival and overall survival in patients with renal cell carcinoma, a form of kidney cancer.